Retatrutide vs Tirzepatide vs Semaglutide: Head-to-Head Comparison of GLP-1 Agents
The landscape of incretin-based therapies has evolved rapidly, moving from single-receptor agonists to dual and now triple agonists. Semaglutide, Tirzepatide, and Retatrutide represent three successive generations of this evolution, each targeting an increasing number of metabolic hormone receptors. For researchers and biohackers tracking this space, understanding how these agents differ in mechanism, efficacy data, and side-effect profiles is essential for interpreting the literature.
This comparison draws on published clinical trial data to contextualize where each peptide stands—and where the research is headed.
Mechanism of Action: One, Two, and Three Receptors
Semaglutide is a selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, slowing gastric emptying, enhancing glucose-dependent insulin secretion, and acting on hypothalamic circuits to reduce appetite. Its long half-life (~165 hours) enables once-weekly dosing thanks to albumin binding and resistance to DPP-4 degradation (Lau et al., 2015).
Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first in its class. It is built on a GIP-based peptide backbone with engineered GLP-1 receptor activity. The addition of GIP receptor agonism appears to enhance insulin sensitivity and lipid metabolism beyond what GLP-1 alone achieves (Frías et al., 2021). Tirzepatide's C20 fatty diacid moiety enables once-weekly dosing through albumin binding.
Retatrutide takes the approach one step further as a triple GLP-1/GIP/glucagon receptor agonist. The glucagon receptor component is hypothesized to increase energy expenditure, promote hepatic lipid oxidation, and reduce liver fat—mechanisms that complement the appetite suppression driven by GLP-1 and the metabolic improvements driven by GIP (Coskun et al., 2022).
Weight Loss Efficacy: Comparing the Numbers
The most striking differentiator across these three peptides is the magnitude of weight loss observed in clinical trials. While cross-trial comparisons have inherent limitations (different populations, endpoints, and durations), the trend is clear.
Semaglutide 2.4 mg (the weight-management dose) produced a mean weight loss of -14.9% from baseline at 68 weeks in the STEP 1 trial, compared to -2.4% with placebo (Wilding et al., 2021). This established semaglutide as a landmark obesity therapy.
Tirzepatide at its highest studied dose (15 mg) achieved a mean weight loss of -20.9% at 72 weeks in the SURMOUNT-1 trial, versus -3.1% with placebo (Jastreboff et al., 2022). The 10 mg dose achieved -19.5%, and the 5 mg dose achieved -15.0%—meaning even tirzepatide's lowest dose roughly matched semaglutide's maximum dose.
Retatrutide demonstrated the most dramatic results in the phase 2 trial published in 2023. At the highest dose (12 mg), participants achieved a mean weight loss of -24.2% at 48 weeks (Jastreboff et al., 2023). Notably, the weight loss curves had not yet plateaued at 48 weeks, suggesting even greater reductions might be observed over longer treatment durations.
Glycemic Control
All three agents show robust glucose-lowering effects, though the data sets differ in population and trial design.
Semaglutide 1.0 mg reduced HbA1c by approximately -1.5 to -1.8 percentage points in the SUSTAIN trials across type 2 diabetes populations (Aroda et al., 201730311-6)). The higher 2.0 mg dose studied in SUSTAIN FORTE achieved reductions of -2.14% from a baseline of ~8.7%.
Tirzepatide showed HbA1c reductions of -2.07% to -2.37% across doses in the SURPASS-1 trial, with up to 97% of participants achieving HbA1c below 7.0% at the 15 mg dose (Rosenstock et al., 2021). In the head-to-head SURPASS-2 trial, tirzepatide at all three doses was superior to semaglutide 1.0 mg for HbA1c reduction (Frías et al., 2021).
Retatrutide's phase 2 data in participants with type 2 diabetes showed HbA1c reductions of up to -2.02% at the 12 mg dose at 36 weeks (Rosenstock et al., 202301053-X)). The glucagon receptor component, while theoretically glycogenolytic, does not appear to compromise glycemic control in the context of concurrent GLP-1 and GIP activity.
Hepatic and Metabolic Effects
One area where retatrutide may offer a distinct advantage is liver fat reduction. The glucagon receptor agonism component promotes hepatic fatty acid oxidation and has shown significant effects on metabolic dysfunction-associated steatotic liver disease (MASLD).
In a dedicated liver imaging substudy from the phase 2 trial, retatrutide at 12 mg reduced liver fat by approximately -82% relative to baseline at 48 weeks. Remarkably, 86% of participants with baseline MASLD achieved normalization of liver fat content (≤5%) (Sanyal et al., 2024). These results surpass those observed with tirzepatide and semaglutide in their respective liver-focused studies.
Tirzepatide has also shown meaningful liver fat reduction—SURMOUNT-3 and dedicated MASLD studies have reported reductions—but the magnitude appears smaller than retatrutide's. Semaglutide demonstrated histological improvement in MASH in the phase 2 study leading to its ongoing phase 3 MASLD program (Newsome et al., 2021), though its effects appear more modest than those of triple agonism.
Side-Effect Profiles
Gastrointestinal adverse events remain the primary tolerability concern across all three agents. The pattern is consistent: nausea, vomiting, diarrhea, and constipation are the most commonly reported side effects, and they are largely dose-dependent and most pronounced during titration.
Discontinuation rates due to adverse events were broadly similar across trials: roughly 4-7% for semaglutide and tirzepatide, and 6% at the highest dose for retatrutide. A notable signal unique to retatrutide was a dose-dependent increase in heart rate (mean +4-5 bpm at 12 mg), which will require close monitoring in phase 3 trials (Jastreboff et al., 2023).
Development Status and Research Outlook
Semaglutide is the most mature molecule in this comparison. It is approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy) and has completed cardiovascular outcomes trials—SELECT demonstrated a 20% reduction in major adverse cardiovascular events in people with overweight/obesity without diabetes (Lincoff et al., 2023).
Tirzepatide is approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Its cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in 2027 (ClinicalTrials.gov NCT04255433).
Retatrutide is currently in phase 3 clinical trials (the TRIUMPH program), with multiple studies enrolling across obesity, type 2 diabetes, MASLD, and sleep apnea indications (ClinicalTrials.gov NCT05929066). Results are expected in 2025-2026. It remains an investigational compound with no regulatory approvals.